Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medicenna Therapeutics Corp T.MDNA

Alternate Symbol(s):  MDNAF

Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company's principal business activity is the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program Targeted Metalloprotease Activated SuperKine (T-MASK) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.


TSX:MDNA - Post by User

Post by HarryGlutenon Oct 07, 2021 7:31am
221 Views
Post# 33978780

Publication of $MDNA 11 (IL-2) study

Publication of $MDNA 11 (IL-2) studyPublication of $MDNA 11 (IL-2) animal studies, incl non-human primates in the prestigious peer-revieed ASCO today.

Title: $MDNA 11 is a long-acting IL-2 superkine that potentiates durable immune response in mouse tumor models and non-human primates. (just google it to find abstract)

Just replicate these results in humans in ph1, and $MDNA is ready for prime-time stock performance.

Prelim results in about two months (December 2021)!


Any questions regarding relvance of non-human primates in immunological drug studies, refer to this research papaer by world-renowed immunotoxicologist Eberhard Buse entitled:

Development of the immune system in the cynomolgus monkey: the appropriate model in human targeted toxicology? (google it)

$nltx $nktr

<< Previous
Bullboard Posts
Next >>